Global Raibizumab Biosimilars Supply, Demand and Key Producers, 2023-2029

Description

The global Raibizumab Biosimilars market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis.

This report studies the global Raibizumab Biosimilars production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Raibizumab Biosimilars, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Raibizumab Biosimilars that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Raibizumab Biosimilars total production and demand, 2018-2029, (Units)
Global Raibizumab Biosimilars total production value, 2018-2029, (USD Million)
Global Raibizumab Biosimilars production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (Units)
Global Raibizumab Biosimilars consumption by region & country, CAGR, 2018-2029 & (Units)
U.S. VS China: Raibizumab Biosimilars domestic production, consumption, key domestic manufacturers and share
Global Raibizumab Biosimilars production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (Units)
Global Raibizumab Biosimilars production by Type, production, value, CAGR, 2018-2029, (USD Million) & (Units)
Global Raibizumab Biosimilars production by Application production, value, CAGR, 2018-2029, (USD Million) & (Units).

This reports profiles key players in the global Raibizumab Biosimilars market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Genentech, Pfizer, Sartorius, Eli Lilly, Bayer, Amgen and PlantForm, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Raibizumab Biosimilars market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Units) and average price (K USD/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Raibizumab Biosimilars Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Raibizumab Biosimilars Market, Segmentation by Type
    AMD
    CNV
    DME

Global Raibizumab Biosimilars Market, Segmentation by Application
    ARMD
    Diabetic Retinopathy
    Macular Edema

Companies Profiled:
    Roche
    Novartis
    Genentech
    Pfizer
    Sartorius
    Eli Lilly
    Bayer
    Amgen
    PlantForm
    PharmaPraxis
    Samsung Bioepis
    Centus
    Cadila Pharmaceuticals
    Dr Reddy's
    Aurobindo Pharma
    Biocad
    MAbxience
    Hetero
    Biocon
    Kirin Biologics
    Mylan
    BeiGene
    Innovent
    Qilu Pharmaceutical
    Hengrui Pharmaceuticals
    Hisun Pharmaceutical
    TOT BIOPHARM
    Luye Pharmaceutical
    Henlius

Key Questions Answered
1. How big is the global Raibizumab Biosimilars market?
2. What is the demand of the global Raibizumab Biosimilars market?
3. What is the year over year growth of the global Raibizumab Biosimilars market?
4. What is the production and production value of the global Raibizumab Biosimilars market?
5. Who are the key producers in the global Raibizumab Biosimilars market?

Table of Contents

1 Supply Summary
    1.1 Raibizumab Biosimilars Introduction
    1.2 World Raibizumab Biosimilars Supply & Forecast
        1.2.1 World Raibizumab Biosimilars Production Value (2018 & 2022 & 2029)
        1.2.2 World Raibizumab Biosimilars Production (2018-2029)
        1.2.3 World Raibizumab Biosimilars Pricing Trends (2018-2029)
    1.3 World Raibizumab Biosimilars Production by Region (Based on Production Site)
        1.3.1 World Raibizumab Biosimilars Production Value by Region (2018-2029)
        1.3.2 World Raibizumab Biosimilars Production by Region (2018-2029)
        1.3.3 World Raibizumab Biosimilars Average Price by Region (2018-2029)
        1.3.4 North America Raibizumab Biosimilars Production (2018-2029)
        1.3.5 Europe Raibizumab Biosimilars Production (2018-2029)
        1.3.6 China Raibizumab Biosimilars Production (2018-2029)
        1.3.7 Japan Raibizumab Biosimilars Production (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Raibizumab Biosimilars Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Raibizumab Biosimilars Major Market Trends

2 Demand Summary
    2.1 World Raibizumab Biosimilars Demand (2018-2029)
    2.2 World Raibizumab Biosimilars Consumption by Region
        2.2.1 World Raibizumab Biosimilars Consumption by Region (2018-2023)
        2.2.2 World Raibizumab Biosimilars Consumption Forecast by Region (2024-2029)
    2.3 United States Raibizumab Biosimilars Consumption (2018-2029)
    2.4 China Raibizumab Biosimilars Consumption (2018-2029)
    2.5 Europe Raibizumab Biosimilars Consumption (2018-2029)
    2.6 Japan Raibizumab Biosimilars Consumption (2018-2029)
    2.7 South Korea Raibizumab Biosimilars Consumption (2018-2029)
    2.8 ASEAN Raibizumab Biosimilars Consumption (2018-2029)
    2.9 India Raibizumab Biosimilars Consumption (2018-2029)

3 World Raibizumab Biosimilars Manufacturers Competitive Analysis
    3.1 World Raibizumab Biosimilars Production Value by Manufacturer (2018-2023)
    3.2 World Raibizumab Biosimilars Production by Manufacturer (2018-2023)
    3.3 World Raibizumab Biosimilars Average Price by Manufacturer (2018-2023)
    3.4 Raibizumab Biosimilars Company Evaluation Quadrant
    3.5 Industry Rank and Concentration Rate (CR)
        3.5.1 Global Raibizumab Biosimilars Industry Rank of Major Manufacturers
        3.5.2 Global Concentration Ratios (CR4) for Raibizumab Biosimilars in 2022
        3.5.3 Global Concentration Ratios (CR8) for Raibizumab Biosimilars in 2022
    3.6 Raibizumab Biosimilars Market: Overall Company Footprint Analysis
        3.6.1 Raibizumab Biosimilars Market: Region Footprint
        3.6.2 Raibizumab Biosimilars Market: Company Product Type Footprint
        3.6.3 Raibizumab Biosimilars Market: Company Product Application Footprint
    3.7 Competitive Environment
        3.7.1 Historical Structure of the Industry
        3.7.2 Barriers of Market Entry
        3.7.3 Factors of Competition
    3.8 New Entrant and Capacity Expansion Plans
    3.9 Mergers, Acquisition, Agreements, and Collaborations

4 United States VS China VS Rest of the World
    4.1 United States VS China: Raibizumab Biosimilars Production Value Comparison
        4.1.1 United States VS China: Raibizumab Biosimilars Production Value Comparison (2018 & 2022 & 2029)
        4.1.2 United States VS China: Raibizumab Biosimilars Production Value Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States VS China: Raibizumab Biosimilars Production Comparison
        4.2.1 United States VS China: Raibizumab Biosimilars Production Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Raibizumab Biosimilars Production Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States VS China: Raibizumab Biosimilars Consumption Comparison
        4.3.1 United States VS China: Raibizumab Biosimilars Consumption Comparison (2018 & 2022 & 2029)
        4.3.2 United States VS China: Raibizumab Biosimilars Consumption Market Share Comparison (2018 & 2022 & 2029)
    4.4 United States Based Raibizumab Biosimilars Manufacturers and Market Share, 2018-2023
        4.4.1 United States Based Raibizumab Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
        4.4.2 United States Based Manufacturers Raibizumab Biosimilars Production Value (2018-2023)
        4.4.3 United States Based Manufacturers Raibizumab Biosimilars Production (2018-2023)
    4.5 China Based Raibizumab Biosimilars Manufacturers and Market Share
        4.5.1 China Based Raibizumab Biosimilars Manufacturers, Headquarters and Production Site (Province, Country)
        4.5.2 China Based Manufacturers Raibizumab Biosimilars Production Value (2018-2023)
        4.5.3 China Based Manufacturers Raibizumab Biosimilars Production (2018-2023)
    4.6 Rest of World Based Raibizumab Biosimilars Manufacturers and Market Share, 2018-2023
        4.6.1 Rest of World Based Raibizumab Biosimilars Manufacturers, Headquarters and Production Site (State, Country)
        4.6.2 Rest of World Based Manufacturers Raibizumab Biosimilars Production Value (2018-2023)
        4.6.3 Rest of World Based Manufacturers Raibizumab Biosimilars Production (2018-2023)

5 Market Analysis by Type
    5.1 World Raibizumab Biosimilars Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 AMD
        5.2.2 CNV
        5.2.3 DME
    5.3 Market Segment by Type
        5.3.1 World Raibizumab Biosimilars Production by Type (2018-2029)
        5.3.2 World Raibizumab Biosimilars Production Value by Type (2018-2029)
        5.3.3 World Raibizumab Biosimilars Average Price by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Raibizumab Biosimilars Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 ARMD
        6.2.2 Diabetic Retinopathy
        6.2.3 Macular Edema
    6.3 Market Segment by Application
        6.3.1 World Raibizumab Biosimilars Production by Application (2018-2029)
        6.3.2 World Raibizumab Biosimilars Production Value by Application (2018-2029)
        6.3.3 World Raibizumab Biosimilars Average Price by Application (2018-2029)

7 Company Profiles
    7.1 Roche
        7.1.1 Roche Details
        7.1.2 Roche Major Business
        7.1.3 Roche Raibizumab Biosimilars Product and Services
        7.1.4 Roche Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.1.5 Roche Recent Developments/Updates
        7.1.6 Roche Competitive Strengths & Weaknesses
    7.2 Novartis
        7.2.1 Novartis Details
        7.2.2 Novartis Major Business
        7.2.3 Novartis Raibizumab Biosimilars Product and Services
        7.2.4 Novartis Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.2.5 Novartis Recent Developments/Updates
        7.2.6 Novartis Competitive Strengths & Weaknesses
    7.3 Genentech
        7.3.1 Genentech Details
        7.3.2 Genentech Major Business
        7.3.3 Genentech Raibizumab Biosimilars Product and Services
        7.3.4 Genentech Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.3.5 Genentech Recent Developments/Updates
        7.3.6 Genentech Competitive Strengths & Weaknesses
    7.4 Pfizer
        7.4.1 Pfizer Details
        7.4.2 Pfizer Major Business
        7.4.3 Pfizer Raibizumab Biosimilars Product and Services
        7.4.4 Pfizer Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.4.5 Pfizer Recent Developments/Updates
        7.4.6 Pfizer Competitive Strengths & Weaknesses
    7.5 Sartorius
        7.5.1 Sartorius Details
        7.5.2 Sartorius Major Business
        7.5.3 Sartorius Raibizumab Biosimilars Product and Services
        7.5.4 Sartorius Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.5.5 Sartorius Recent Developments/Updates
        7.5.6 Sartorius Competitive Strengths & Weaknesses
    7.6 Eli Lilly
        7.6.1 Eli Lilly Details
        7.6.2 Eli Lilly Major Business
        7.6.3 Eli Lilly Raibizumab Biosimilars Product and Services
        7.6.4 Eli Lilly Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.6.5 Eli Lilly Recent Developments/Updates
        7.6.6 Eli Lilly Competitive Strengths & Weaknesses
    7.7 Bayer
        7.7.1 Bayer Details
        7.7.2 Bayer Major Business
        7.7.3 Bayer Raibizumab Biosimilars Product and Services
        7.7.4 Bayer Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.7.5 Bayer Recent Developments/Updates
        7.7.6 Bayer Competitive Strengths & Weaknesses
    7.8 Amgen
        7.8.1 Amgen Details
        7.8.2 Amgen Major Business
        7.8.3 Amgen Raibizumab Biosimilars Product and Services
        7.8.4 Amgen Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.8.5 Amgen Recent Developments/Updates
        7.8.6 Amgen Competitive Strengths & Weaknesses
    7.9 PlantForm
        7.9.1 PlantForm Details
        7.9.2 PlantForm Major Business
        7.9.3 PlantForm Raibizumab Biosimilars Product and Services
        7.9.4 PlantForm Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.9.5 PlantForm Recent Developments/Updates
        7.9.6 PlantForm Competitive Strengths & Weaknesses
    7.10 PharmaPraxis
        7.10.1 PharmaPraxis Details
        7.10.2 PharmaPraxis Major Business
        7.10.3 PharmaPraxis Raibizumab Biosimilars Product and Services
        7.10.4 PharmaPraxis Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.10.5 PharmaPraxis Recent Developments/Updates
        7.10.6 PharmaPraxis Competitive Strengths & Weaknesses
    7.11 Samsung Bioepis
        7.11.1 Samsung Bioepis Details
        7.11.2 Samsung Bioepis Major Business
        7.11.3 Samsung Bioepis Raibizumab Biosimilars Product and Services
        7.11.4 Samsung Bioepis Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.11.5 Samsung Bioepis Recent Developments/Updates
        7.11.6 Samsung Bioepis Competitive Strengths & Weaknesses
    7.12 Centus
        7.12.1 Centus Details
        7.12.2 Centus Major Business
        7.12.3 Centus Raibizumab Biosimilars Product and Services
        7.12.4 Centus Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.12.5 Centus Recent Developments/Updates
        7.12.6 Centus Competitive Strengths & Weaknesses
    7.13 Cadila Pharmaceuticals
        7.13.1 Cadila Pharmaceuticals Details
        7.13.2 Cadila Pharmaceuticals Major Business
        7.13.3 Cadila Pharmaceuticals Raibizumab Biosimilars Product and Services
        7.13.4 Cadila Pharmaceuticals Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.13.5 Cadila Pharmaceuticals Recent Developments/Updates
        7.13.6 Cadila Pharmaceuticals Competitive Strengths & Weaknesses
    7.14 Dr Reddy's
        7.14.1 Dr Reddy's Details
        7.14.2 Dr Reddy's Major Business
        7.14.3 Dr Reddy's Raibizumab Biosimilars Product and Services
        7.14.4 Dr Reddy's Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.14.5 Dr Reddy's Recent Developments/Updates
        7.14.6 Dr Reddy's Competitive Strengths & Weaknesses
    7.15 Aurobindo Pharma
        7.15.1 Aurobindo Pharma Details
        7.15.2 Aurobindo Pharma Major Business
        7.15.3 Aurobindo Pharma Raibizumab Biosimilars Product and Services
        7.15.4 Aurobindo Pharma Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.15.5 Aurobindo Pharma Recent Developments/Updates
        7.15.6 Aurobindo Pharma Competitive Strengths & Weaknesses
    7.16 Biocad
        7.16.1 Biocad Details
        7.16.2 Biocad Major Business
        7.16.3 Biocad Raibizumab Biosimilars Product and Services
        7.16.4 Biocad Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.16.5 Biocad Recent Developments/Updates
        7.16.6 Biocad Competitive Strengths & Weaknesses
    7.17 MAbxience
        7.17.1 MAbxience Details
        7.17.2 MAbxience Major Business
        7.17.3 MAbxience Raibizumab Biosimilars Product and Services
        7.17.4 MAbxience Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.17.5 MAbxience Recent Developments/Updates
        7.17.6 MAbxience Competitive Strengths & Weaknesses
    7.18 Hetero
        7.18.1 Hetero Details
        7.18.2 Hetero Major Business
        7.18.3 Hetero Raibizumab Biosimilars Product and Services
        7.18.4 Hetero Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.18.5 Hetero Recent Developments/Updates
        7.18.6 Hetero Competitive Strengths & Weaknesses
    7.19 Biocon
        7.19.1 Biocon Details
        7.19.2 Biocon Major Business
        7.19.3 Biocon Raibizumab Biosimilars Product and Services
        7.19.4 Biocon Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.19.5 Biocon Recent Developments/Updates
        7.19.6 Biocon Competitive Strengths & Weaknesses
    7.20 Kirin Biologics
        7.20.1 Kirin Biologics Details
        7.20.2 Kirin Biologics Major Business
        7.20.3 Kirin Biologics Raibizumab Biosimilars Product and Services
        7.20.4 Kirin Biologics Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.20.5 Kirin Biologics Recent Developments/Updates
        7.20.6 Kirin Biologics Competitive Strengths & Weaknesses
    7.21 Mylan
        7.21.1 Mylan Details
        7.21.2 Mylan Major Business
        7.21.3 Mylan Raibizumab Biosimilars Product and Services
        7.21.4 Mylan Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.21.5 Mylan Recent Developments/Updates
        7.21.6 Mylan Competitive Strengths & Weaknesses
    7.22 BeiGene
        7.22.1 BeiGene Details
        7.22.2 BeiGene Major Business
        7.22.3 BeiGene Raibizumab Biosimilars Product and Services
        7.22.4 BeiGene Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.22.5 BeiGene Recent Developments/Updates
        7.22.6 BeiGene Competitive Strengths & Weaknesses
    7.23 Innovent
        7.23.1 Innovent Details
        7.23.2 Innovent Major Business
        7.23.3 Innovent Raibizumab Biosimilars Product and Services
        7.23.4 Innovent Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.23.5 Innovent Recent Developments/Updates
        7.23.6 Innovent Competitive Strengths & Weaknesses
    7.24 Qilu Pharmaceutical
        7.24.1 Qilu Pharmaceutical Details
        7.24.2 Qilu Pharmaceutical Major Business
        7.24.3 Qilu Pharmaceutical Raibizumab Biosimilars Product and Services
        7.24.4 Qilu Pharmaceutical Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.24.5 Qilu Pharmaceutical Recent Developments/Updates
        7.24.6 Qilu Pharmaceutical Competitive Strengths & Weaknesses
    7.25 Hengrui Pharmaceuticals
        7.25.1 Hengrui Pharmaceuticals Details
        7.25.2 Hengrui Pharmaceuticals Major Business
        7.25.3 Hengrui Pharmaceuticals Raibizumab Biosimilars Product and Services
        7.25.4 Hengrui Pharmaceuticals Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.25.5 Hengrui Pharmaceuticals Recent Developments/Updates
        7.25.6 Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
    7.26 Hisun Pharmaceutical
        7.26.1 Hisun Pharmaceutical Details
        7.26.2 Hisun Pharmaceutical Major Business
        7.26.3 Hisun Pharmaceutical Raibizumab Biosimilars Product and Services
        7.26.4 Hisun Pharmaceutical Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.26.5 Hisun Pharmaceutical Recent Developments/Updates
        7.26.6 Hisun Pharmaceutical Competitive Strengths & Weaknesses
    7.27 TOT BIOPHARM
        7.27.1 TOT BIOPHARM Details
        7.27.2 TOT BIOPHARM Major Business
        7.27.3 TOT BIOPHARM Raibizumab Biosimilars Product and Services
        7.27.4 TOT BIOPHARM Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.27.5 TOT BIOPHARM Recent Developments/Updates
        7.27.6 TOT BIOPHARM Competitive Strengths & Weaknesses
    7.28 Luye Pharmaceutical
        7.28.1 Luye Pharmaceutical Details
        7.28.2 Luye Pharmaceutical Major Business
        7.28.3 Luye Pharmaceutical Raibizumab Biosimilars Product and Services
        7.28.4 Luye Pharmaceutical Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.28.5 Luye Pharmaceutical Recent Developments/Updates
        7.28.6 Luye Pharmaceutical Competitive Strengths & Weaknesses
    7.29 Henlius
        7.29.1 Henlius Details
        7.29.2 Henlius Major Business
        7.29.3 Henlius Raibizumab Biosimilars Product and Services
        7.29.4 Henlius Raibizumab Biosimilars Production, Price, Value, Gross Margin and Market Share (2018-2023)
        7.29.5 Henlius Recent Developments/Updates
        7.29.6 Henlius Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Raibizumab Biosimilars Industry Chain
    8.2 Raibizumab Biosimilars Upstream Analysis
        8.2.1 Raibizumab Biosimilars Core Raw Materials
        8.2.2 Main Manufacturers of Raibizumab Biosimilars Core Raw Materials
    8.3 Midstream Analysis
    8.4 Downstream Analysis
    8.5 Raibizumab Biosimilars Production Mode
    8.6 Raibizumab Biosimilars Procurement Model
    8.7 Raibizumab Biosimilars Industry Sales Model and Sales Channels
        8.7.1 Raibizumab Biosimilars Sales Model
        8.7.2 Raibizumab Biosimilars Typical Customers

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Raibizumab Biosimilars Production Value by Region (2018, 2022 and 2029) & (USD Million)
    Table 2. World Raibizumab Biosimilars Production Value by Region (2018-2023) & (USD Million)
    Table 3. World Raibizumab Biosimilars Production Value by Region (2024-2029) & (USD Million)
    Table 4. World Raibizumab Biosimilars Production Value Market Share by Region (2018-2023)
    Table 5. World Raibizumab Biosimilars Production Value Market Share by Region (2024-2029)
    Table 6. World Raibizumab Biosimilars Production by Region (2018-2023) & (Units)
    Table 7. World Raibizumab Biosimilars Production by Region (2024-2029) & (Units)
    Table 8. World Raibizumab Biosimilars Production Market Share by Region (2018-2023)
    Table 9. World Raibizumab Biosimilars Production Market Share by Region (2024-2029)
    Table 10. World Raibizumab Biosimilars Average Price by Region (2018-2023) & (K USD/Unit)
    Table 11. World Raibizumab Biosimilars Average Price by Region (2024-2029) & (K USD/Unit)
    Table 12. Raibizumab Biosimilars Major Market Trends
    Table 13. World Raibizumab Biosimilars Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (Units)
    Table 14. World Raibizumab Biosimilars Consumption by Region (2018-2023) & (Units)
    Table 15. World Raibizumab Biosimilars Consumption Forecast by Region (2024-2029) & (Units)
    Table 16. World Raibizumab Biosimilars Production Value by Manufacturer (2018-2023) & (USD Million)
    Table 17. Production Value Market Share of Key Raibizumab Biosimilars Producers in 2022
    Table 18. World Raibizumab Biosimilars Production by Manufacturer (2018-2023) & (Units)
    Table 19. Production Market Share of Key Raibizumab Biosimilars Producers in 2022
    Table 20. World Raibizumab Biosimilars Average Price by Manufacturer (2018-2023) & (K USD/Unit)
    Table 21. Global Raibizumab Biosimilars Company Evaluation Quadrant
    Table 22. World Raibizumab Biosimilars Industry Rank of Major Manufacturers, Based on Production Value in 2022
    Table 23. Head Office and Raibizumab Biosimilars Production Site of Key Manufacturer
    Table 24. Raibizumab Biosimilars Market: Company Product Type Footprint
    Table 25. Raibizumab Biosimilars Market: Company Product Application Footprint
    Table 26. Raibizumab Biosimilars Competitive Factors
    Table 27. Raibizumab Biosimilars New Entrant and Capacity Expansion Plans
    Table 28. Raibizumab Biosimilars Mergers & Acquisitions Activity
    Table 29. United States VS China Raibizumab Biosimilars Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 30. United States VS China Raibizumab Biosimilars Production Comparison, (2018 & 2022 & 2029) & (Units)
    Table 31. United States VS China Raibizumab Biosimilars Consumption Comparison, (2018 & 2022 & 2029) & (Units)
    Table 32. United States Based Raibizumab Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
    Table 33. United States Based Manufacturers Raibizumab Biosimilars Production Value, (2018-2023) & (USD Million)
    Table 34. United States Based Manufacturers Raibizumab Biosimilars Production Value Market Share (2018-2023)
    Table 35. United States Based Manufacturers Raibizumab Biosimilars Production (2018-2023) & (Units)
    Table 36. United States Based Manufacturers Raibizumab Biosimilars Production Market Share (2018-2023)
    Table 37. China Based Raibizumab Biosimilars Manufacturers, Headquarters and Production Site (Province, Country)
    Table 38. China Based Manufacturers Raibizumab Biosimilars Production Value, (2018-2023) & (USD Million)
    Table 39. China Based Manufacturers Raibizumab Biosimilars Production Value Market Share (2018-2023)
    Table 40. China Based Manufacturers Raibizumab Biosimilars Production (2018-2023) & (Units)
    Table 41. China Based Manufacturers Raibizumab Biosimilars Production Market Share (2018-2023)
    Table 42. Rest of World Based Raibizumab Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
    Table 43. Rest of World Based Manufacturers Raibizumab Biosimilars Production Value, (2018-2023) & (USD Million)
    Table 44. Rest of World Based Manufacturers Raibizumab Biosimilars Production Value Market Share (2018-2023)
    Table 45. Rest of World Based Manufacturers Raibizumab Biosimilars Production (2018-2023) & (Units)
    Table 46. Rest of World Based Manufacturers Raibizumab Biosimilars Production Market Share (2018-2023)
    Table 47. World Raibizumab Biosimilars Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 48. World Raibizumab Biosimilars Production by Type (2018-2023) & (Units)
    Table 49. World Raibizumab Biosimilars Production by Type (2024-2029) & (Units)
    Table 50. World Raibizumab Biosimilars Production Value by Type (2018-2023) & (USD Million)
    Table 51. World Raibizumab Biosimilars Production Value by Type (2024-2029) & (USD Million)
    Table 52. World Raibizumab Biosimilars Average Price by Type (2018-2023) & (K USD/Unit)
    Table 53. World Raibizumab Biosimilars Average Price by Type (2024-2029) & (K USD/Unit)
    Table 54. World Raibizumab Biosimilars Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 55. World Raibizumab Biosimilars Production by Application (2018-2023) & (Units)
    Table 56. World Raibizumab Biosimilars Production by Application (2024-2029) & (Units)
    Table 57. World Raibizumab Biosimilars Production Value by Application (2018-2023) & (USD Million)
    Table 58. World Raibizumab Biosimilars Production Value by Application (2024-2029) & (USD Million)
    Table 59. World Raibizumab Biosimilars Average Price by Application (2018-2023) & (K USD/Unit)
    Table 60. World Raibizumab Biosimilars Average Price by Application (2024-2029) & (K USD/Unit)
    Table 61. Roche Basic Information, Manufacturing Base and Competitors
    Table 62. Roche Major Business
    Table 63. Roche Raibizumab Biosimilars Product and Services
    Table 64. Roche Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 65. Roche Recent Developments/Updates
    Table 66. Roche Competitive Strengths & Weaknesses
    Table 67. Novartis Basic Information, Manufacturing Base and Competitors
    Table 68. Novartis Major Business
    Table 69. Novartis Raibizumab Biosimilars Product and Services
    Table 70. Novartis Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 71. Novartis Recent Developments/Updates
    Table 72. Novartis Competitive Strengths & Weaknesses
    Table 73. Genentech Basic Information, Manufacturing Base and Competitors
    Table 74. Genentech Major Business
    Table 75. Genentech Raibizumab Biosimilars Product and Services
    Table 76. Genentech Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 77. Genentech Recent Developments/Updates
    Table 78. Genentech Competitive Strengths & Weaknesses
    Table 79. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 80. Pfizer Major Business
    Table 81. Pfizer Raibizumab Biosimilars Product and Services
    Table 82. Pfizer Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 83. Pfizer Recent Developments/Updates
    Table 84. Pfizer Competitive Strengths & Weaknesses
    Table 85. Sartorius Basic Information, Manufacturing Base and Competitors
    Table 86. Sartorius Major Business
    Table 87. Sartorius Raibizumab Biosimilars Product and Services
    Table 88. Sartorius Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 89. Sartorius Recent Developments/Updates
    Table 90. Sartorius Competitive Strengths & Weaknesses
    Table 91. Eli Lilly Basic Information, Manufacturing Base and Competitors
    Table 92. Eli Lilly Major Business
    Table 93. Eli Lilly Raibizumab Biosimilars Product and Services
    Table 94. Eli Lilly Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 95. Eli Lilly Recent Developments/Updates
    Table 96. Eli Lilly Competitive Strengths & Weaknesses
    Table 97. Bayer Basic Information, Manufacturing Base and Competitors
    Table 98. Bayer Major Business
    Table 99. Bayer Raibizumab Biosimilars Product and Services
    Table 100. Bayer Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 101. Bayer Recent Developments/Updates
    Table 102. Bayer Competitive Strengths & Weaknesses
    Table 103. Amgen Basic Information, Manufacturing Base and Competitors
    Table 104. Amgen Major Business
    Table 105. Amgen Raibizumab Biosimilars Product and Services
    Table 106. Amgen Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 107. Amgen Recent Developments/Updates
    Table 108. Amgen Competitive Strengths & Weaknesses
    Table 109. PlantForm Basic Information, Manufacturing Base and Competitors
    Table 110. PlantForm Major Business
    Table 111. PlantForm Raibizumab Biosimilars Product and Services
    Table 112. PlantForm Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 113. PlantForm Recent Developments/Updates
    Table 114. PlantForm Competitive Strengths & Weaknesses
    Table 115. PharmaPraxis Basic Information, Manufacturing Base and Competitors
    Table 116. PharmaPraxis Major Business
    Table 117. PharmaPraxis Raibizumab Biosimilars Product and Services
    Table 118. PharmaPraxis Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 119. PharmaPraxis Recent Developments/Updates
    Table 120. PharmaPraxis Competitive Strengths & Weaknesses
    Table 121. Samsung Bioepis Basic Information, Manufacturing Base and Competitors
    Table 122. Samsung Bioepis Major Business
    Table 123. Samsung Bioepis Raibizumab Biosimilars Product and Services
    Table 124. Samsung Bioepis Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 125. Samsung Bioepis Recent Developments/Updates
    Table 126. Samsung Bioepis Competitive Strengths & Weaknesses
    Table 127. Centus Basic Information, Manufacturing Base and Competitors
    Table 128. Centus Major Business
    Table 129. Centus Raibizumab Biosimilars Product and Services
    Table 130. Centus Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 131. Centus Recent Developments/Updates
    Table 132. Centus Competitive Strengths & Weaknesses
    Table 133. Cadila Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 134. Cadila Pharmaceuticals Major Business
    Table 135. Cadila Pharmaceuticals Raibizumab Biosimilars Product and Services
    Table 136. Cadila Pharmaceuticals Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 137. Cadila Pharmaceuticals Recent Developments/Updates
    Table 138. Cadila Pharmaceuticals Competitive Strengths & Weaknesses
    Table 139. Dr Reddy's Basic Information, Manufacturing Base and Competitors
    Table 140. Dr Reddy's Major Business
    Table 141. Dr Reddy's Raibizumab Biosimilars Product and Services
    Table 142. Dr Reddy's Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 143. Dr Reddy's Recent Developments/Updates
    Table 144. Dr Reddy's Competitive Strengths & Weaknesses
    Table 145. Aurobindo Pharma Basic Information, Manufacturing Base and Competitors
    Table 146. Aurobindo Pharma Major Business
    Table 147. Aurobindo Pharma Raibizumab Biosimilars Product and Services
    Table 148. Aurobindo Pharma Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 149. Aurobindo Pharma Recent Developments/Updates
    Table 150. Aurobindo Pharma Competitive Strengths & Weaknesses
    Table 151. Biocad Basic Information, Manufacturing Base and Competitors
    Table 152. Biocad Major Business
    Table 153. Biocad Raibizumab Biosimilars Product and Services
    Table 154. Biocad Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 155. Biocad Recent Developments/Updates
    Table 156. Biocad Competitive Strengths & Weaknesses
    Table 157. MAbxience Basic Information, Manufacturing Base and Competitors
    Table 158. MAbxience Major Business
    Table 159. MAbxience Raibizumab Biosimilars Product and Services
    Table 160. MAbxience Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 161. MAbxience Recent Developments/Updates
    Table 162. MAbxience Competitive Strengths & Weaknesses
    Table 163. Hetero Basic Information, Manufacturing Base and Competitors
    Table 164. Hetero Major Business
    Table 165. Hetero Raibizumab Biosimilars Product and Services
    Table 166. Hetero Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 167. Hetero Recent Developments/Updates
    Table 168. Hetero Competitive Strengths & Weaknesses
    Table 169. Biocon Basic Information, Manufacturing Base and Competitors
    Table 170. Biocon Major Business
    Table 171. Biocon Raibizumab Biosimilars Product and Services
    Table 172. Biocon Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 173. Biocon Recent Developments/Updates
    Table 174. Biocon Competitive Strengths & Weaknesses
    Table 175. Kirin Biologics Basic Information, Manufacturing Base and Competitors
    Table 176. Kirin Biologics Major Business
    Table 177. Kirin Biologics Raibizumab Biosimilars Product and Services
    Table 178. Kirin Biologics Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 179. Kirin Biologics Recent Developments/Updates
    Table 180. Kirin Biologics Competitive Strengths & Weaknesses
    Table 181. Mylan Basic Information, Manufacturing Base and Competitors
    Table 182. Mylan Major Business
    Table 183. Mylan Raibizumab Biosimilars Product and Services
    Table 184. Mylan Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 185. Mylan Recent Developments/Updates
    Table 186. Mylan Competitive Strengths & Weaknesses
    Table 187. BeiGene Basic Information, Manufacturing Base and Competitors
    Table 188. BeiGene Major Business
    Table 189. BeiGene Raibizumab Biosimilars Product and Services
    Table 190. BeiGene Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 191. BeiGene Recent Developments/Updates
    Table 192. BeiGene Competitive Strengths & Weaknesses
    Table 193. Innovent Basic Information, Manufacturing Base and Competitors
    Table 194. Innovent Major Business
    Table 195. Innovent Raibizumab Biosimilars Product and Services
    Table 196. Innovent Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 197. Innovent Recent Developments/Updates
    Table 198. Innovent Competitive Strengths & Weaknesses
    Table 199. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
    Table 200. Qilu Pharmaceutical Major Business
    Table 201. Qilu Pharmaceutical Raibizumab Biosimilars Product and Services
    Table 202. Qilu Pharmaceutical Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 203. Qilu Pharmaceutical Recent Developments/Updates
    Table 204. Qilu Pharmaceutical Competitive Strengths & Weaknesses
    Table 205. Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
    Table 206. Hengrui Pharmaceuticals Major Business
    Table 207. Hengrui Pharmaceuticals Raibizumab Biosimilars Product and Services
    Table 208. Hengrui Pharmaceuticals Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 209. Hengrui Pharmaceuticals Recent Developments/Updates
    Table 210. Hengrui Pharmaceuticals Competitive Strengths & Weaknesses
    Table 211. Hisun Pharmaceutical Basic Information, Manufacturing Base and Competitors
    Table 212. Hisun Pharmaceutical Major Business
    Table 213. Hisun Pharmaceutical Raibizumab Biosimilars Product and Services
    Table 214. Hisun Pharmaceutical Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 215. Hisun Pharmaceutical Recent Developments/Updates
    Table 216. Hisun Pharmaceutical Competitive Strengths & Weaknesses
    Table 217. TOT BIOPHARM Basic Information, Manufacturing Base and Competitors
    Table 218. TOT BIOPHARM Major Business
    Table 219. TOT BIOPHARM Raibizumab Biosimilars Product and Services
    Table 220. TOT BIOPHARM Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 221. TOT BIOPHARM Recent Developments/Updates
    Table 222. TOT BIOPHARM Competitive Strengths & Weaknesses
    Table 223. Luye Pharmaceutical Basic Information, Manufacturing Base and Competitors
    Table 224. Luye Pharmaceutical Major Business
    Table 225. Luye Pharmaceutical Raibizumab Biosimilars Product and Services
    Table 226. Luye Pharmaceutical Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 227. Luye Pharmaceutical Recent Developments/Updates
    Table 228. Henlius Basic Information, Manufacturing Base and Competitors
    Table 229. HenliusMajor Business
    Table 230. Henlius Raibizumab Biosimilars Product and Services
    Table 231. Henlius Raibizumab Biosimilars Production (Units), Price (K USD/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
    Table 232. Global Key Players of Raibizumab Biosimilars Upstream (Raw Materials)
    Table 233. Raibizumab Biosimilars Typical Customers
    Table 234. Raibizumab Biosimilars Typical Distributors
List of Figure
    Figure 1. Raibizumab Biosimilars Picture
    Figure 2. World Raibizumab Biosimilars Production Value: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Raibizumab Biosimilars Production Value and Forecast (2018-2029) & (USD Million)
    Figure 4. World Raibizumab Biosimilars Production (2018-2029) & (Units)
    Figure 5. World Raibizumab Biosimilars Average Price (2018-2029) & (K USD/Unit)
    Figure 6. World Raibizumab Biosimilars Production Value Market Share by Region (2018-2029)
    Figure 7. World Raibizumab Biosimilars Production Market Share by Region (2018-2029)
    Figure 8. North America Raibizumab Biosimilars Production (2018-2029) & (Units)
    Figure 9. Europe Raibizumab Biosimilars Production (2018-2029) & (Units)
    Figure 10. China Raibizumab Biosimilars Production (2018-2029) & (Units)
    Figure 11. Japan Raibizumab Biosimilars Production (2018-2029) & (Units)
    Figure 12. Raibizumab Biosimilars Market Drivers
    Figure 13. Factors Affecting Demand
    Figure 14. World Raibizumab Biosimilars Consumption (2018-2029) & (Units)
    Figure 15. World Raibizumab Biosimilars Consumption Market Share by Region (2018-2029)
    Figure 16. United States Raibizumab Biosimilars Consumption (2018-2029) & (Units)
    Figure 17. China Raibizumab Biosimilars Consumption (2018-2029) & (Units)
    Figure 18. Europe Raibizumab Biosimilars Consumption (2018-2029) & (Units)
    Figure 19. Japan Raibizumab Biosimilars Consumption (2018-2029) & (Units)
    Figure 20. South Korea Raibizumab Biosimilars Consumption (2018-2029) & (Units)
    Figure 21. ASEAN Raibizumab Biosimilars Consumption (2018-2029) & (Units)
    Figure 22. India Raibizumab Biosimilars Consumption (2018-2029) & (Units)
    Figure 23. Producer Shipments of Raibizumab Biosimilars by Manufacturer Revenue ($MM) and Market Share (%): 2022
    Figure 24. Global Four-firm Concentration Ratios (CR4) for Raibizumab Biosimilars Markets in 2022
    Figure 25. Global Four-firm Concentration Ratios (CR8) for Raibizumab Biosimilars Markets in 2022
    Figure 26. United States VS China: Raibizumab Biosimilars Production Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 27. United States VS China: Raibizumab Biosimilars Production Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Raibizumab Biosimilars Consumption Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. United States Based Manufacturers Raibizumab Biosimilars Production Market Share 2022
    Figure 30. China Based Manufacturers Raibizumab Biosimilars Production Market Share 2022
    Figure 31. Rest of World Based Manufacturers Raibizumab Biosimilars Production Market Share 2022
    Figure 32. World Raibizumab Biosimilars Production Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 33. World Raibizumab Biosimilars Production Value Market Share by Type in 2022
    Figure 34. AMD
    Figure 35. CNV
    Figure 36. DME
    Figure 37. World Raibizumab Biosimilars Production Market Share by Type (2018-2029)
    Figure 38. World Raibizumab Biosimilars Production Value Market Share by Type (2018-2029)
    Figure 39. World Raibizumab Biosimilars Average Price by Type (2018-2029) & (K USD/Unit)
    Figure 40. World Raibizumab Biosimilars Production Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 41. World Raibizumab Biosimilars Production Value Market Share by Application in 2022
    Figure 42. ARMD
    Figure 43. Diabetic Retinopathy
    Figure 44. Macular Edema
    Figure 45. World Raibizumab Biosimilars Production Market Share by Application (2018-2029)
    Figure 46. World Raibizumab Biosimilars Production Value Market Share by Application (2018-2029)
    Figure 47. World Raibizumab Biosimilars Average Price by Application (2018-2029) & (K USD/Unit)
    Figure 48. Raibizumab Biosimilars Industry Chain
    Figure 49. Raibizumab Biosimilars Procurement Model
    Figure 50. Raibizumab Biosimilars Sales Model
    Figure 51. Raibizumab Biosimilars Sales Channels, Direct Sales, and Distribution
    Figure 52. Methodology
    Figure 53. Research Process and Data Source

Companies Mentioned

Roche
Novartis
Genentech
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy's
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
Luye Pharmaceutical
Henlius